Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2016-12, Vol.122 (24), p.3856-3864
Hauptverfasser:	Sherman, Steven I., Clary, Douglas O., Elisei, Rossella, Schlumberger, Martin J., Cohen, Ezra E. W., Schöffski, Patrick, Wirth, Lori J., Mangeshkar, Milan, Aftab, Dana T., Brose, Marcia S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anilides - therapeutic use cabozantinib Disease-Free Survival Double-Blind Method Humans medullary thyroid cancer Mutation - genetics Proto-Oncogene Proteins c-ret - genetics Pyridines - therapeutic use RAS ras Proteins - genetics RET Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics Thyroid Neoplasms - pathology tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P
ISSN:	0008-543X 1097-0142
DOI:	10.1002/cncr.30252